Dare Bioscience Files 8-K with Material Agreement Details
Ticker: DARE · Form: 8-K · Filed: Oct 23, 2024 · CIK: 1401914
Sentiment: neutral
Topics: material-agreement, filing, corporate-update
TL;DR
Dare Bioscience just filed an 8-K for a material definitive agreement - check for details!
AI Summary
On October 23, 2024, Dare Bioscience, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements/exhibits. The company, previously known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This 8-K filing signals a significant development for Dare Bioscience, Inc., potentially involving a new contract or partnership that could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new financial obligations or strategic shifts, carrying inherent risks that require careful evaluation.
Key Players & Entities
- Dare Bioscience, Inc. (company) — Registrant
- October 23, 2024 (date) — Date of earliest event reported
- Cerulean Pharma Inc. (company) — Former company name
- Tempo Pharmaceuticals Inc (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- San Diego, CA (location) — Principal Executive Office Location
FAQ
What is the nature of the material definitive agreement filed by Dare Bioscience, Inc.?
The 8-K filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text excerpt. Further review of the full filing is required.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 23, 2024.
What were Dare Bioscience, Inc.'s previous company names?
Dare Bioscience, Inc. was previously known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.
In which state is Dare Bioscience, Inc. incorporated?
Dare Bioscience, Inc. is incorporated in Delaware.
Where are Dare Bioscience, Inc.'s principal executive offices located?
Dare Bioscience, Inc.'s principal executive offices are located at 3655 Nobel Drive, Suite 260, San Diego, CA 92122.
Filing Stats: 1,487 words · 6 min read · ~5 pages · Grade level 14 · Accepted 2024-10-23 12:31:39
Key Financial Figures
- $10.0 million — re entitled to receive funding of up to $10.0 million (the "Award Amount") in milestone-based
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex99-1.htm (EX-99.1) — 27KB
- 0001493152-24-042193.txt ( ) — 258KB
- dare-20241023.xsd (EX-101.SCH) — 3KB
- dare-20241023_lab.xml (EX-101.LAB) — 33KB
- dare-20241023_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will,"
Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those anticipated as a result of various factors, including, without limitation, the risks and uncertainties inherent in the research and development of investigational drug products, including DARE-HPV, Dar's ability to meet the milestones required for receipt of payments under the Agreement, or at all, and Dar's ability to continue as a going concern. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in the forward-looking statements, as well as risks relating to Dar's business in general, please refer to Dar's annual report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 28, 2024, its quarterly report on Form 10-Q filed with the SEC on August 12, 2024, and its current reports on Form 8-K subsequently filed with the SEC. You are urged to consider these factors carefully in evaluating the forward-looking statements in this report and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. Unless otherwise required by law, Dar expressly disclaims any obligation to update publicly any forward-looking statements, whether as result of new information, future events or otherwise. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued on October 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL documen
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: October 23, 2024 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer